(formerly) Department of science and technology, National Academy of Medicine

Lifearc has developed more than 10 listed monoclonal antibody drugs such as Avastin, Herceptin and keytruda. The sy-006 LRRK2 inhibitor developed by Suzhou Yabao in cooperation with lifearc is a global best in class drug with the treatment indication of Parkinson's disease. The project plans to start phase I clinical research in 2022.

Next:Rosen Health Institute of Canada